Department of Materials Science & Engineering, University of Florida, Gainesville, FL 32611-6400, USA.
Int J Mol Sci. 2013 Aug 26;14(9):17501-10. doi: 10.3390/ijms140917501.
Feraheme, is a recently FDA-cleared superparamagnetic iron oxide nanoparticle (SPION)-based MRI contrast agent that is also employed in the treatment of iron deficiency anemia. Feraheme nanoparticles have a hydrodynamic diameter of 30 nm and consist of iron oxide crystallites complexed with a low molecular weight, semi-synthetic carbohydrate. These features are attractive for other potential biomedical applications such as magnetic fluid hyperthermia (MFH), since the carboxylated polymer coating affords functionalization of the particle surface and the size allows for accumulation in highly vascularized tumors via the enhanced permeability and retention effect. This work presents morphological and magnetic characterization of Feraheme by transmission electron microscopy (TEM), Energy dispersive X-ray spectroscopy (EDX), and superconducting quantum interference device (SQUID) magnetometry. Additionally, the results of an initial evaluation of the suitability of Feraheme for MFH applications are described, and the data indicate the particles possess promising properties for this application.
Feraheme 是一种最近获得美国食品药品监督管理局（FDA）批准的超顺磁性氧化铁纳米颗粒（SPION）为基础的磁共振成像（MRI）造影剂，也用于治疗缺铁性贫血。Feraheme 纳米颗粒的水动力学直径为 30nm，由氧化铁晶体与低分子量、半合成碳水化合物复合而成。这些特性对于其他潜在的生物医学应用具有吸引力，如磁流体热疗（MFH），因为羧基化聚合物涂层可使颗粒表面功能化，且尺寸允许通过增强的通透性和保留效应在高度血管化的肿瘤中积累。本工作通过透射电子显微镜（TEM）、能量色散 X 射线光谱（EDX）和超导量子干涉装置（SQUID）磁强计对 Feraheme 的形态和磁性进行了表征。此外，还描述了对 Feraheme 用于 MFH 应用的适用性的初步评估结果，数据表明这些颗粒具有该应用的有前途的特性。
